Day 1

Keynote I: Accelerating Innovation & Reimagining Health

• Speaker: Stephen M. Hahn, MD, FASTRO, Nucleus RadioPharma

Radiopharmaceutical Program Justification and Initial Start-up
Moderator: Ramji R. Rajendran, MD, PhD, Radiation Oncology Consultants, Ltd.

• Practice Economics for Radiopharmaceutical Therapy: From Mission to Margin
  • Dustin L. Boothe, MD, Intermountain Health, Utah Cancer Specialists
• Space Requirements for RPT Administration
  • J. Travis Mendel, MD, Rio Grande Cancer Specialists
• The RAM License and SOP Development
  • Ashley Cockerham, MSJ, Mercurie Consulting, LLC
• Clinic and Staffing Needs for RPT Delivery
  • Brett E. Lewis, MD, PhD, Hackensack University Medical Center
• Q&A

Keynote II: Radiopharmaceutical Impact Review: Patients, Performance, Potential and People
Moderator: Brandon Mancini, MD, MBA, BAMF Health, Michigan State University

• Speaker: Johannes Czernin, MD, University of California, Los Angeles

Authorized User Pathways and Physicist Training in Radiopharmaceutical Therapy
Moderator: Xinxin Zhang, PhD, Rutgers Cancer Institute of New Jersey/Robert Wood Johnson University Hospital

• The Path to Authorized User for Unsealed Byproduct Material
  • Robert J. Tokarz, MS, DABR, RJ Tokarz Medical Imaging Radiation Safety Corp
• Physicist Training in RPT: The Beginnings of Structured Programs
  • Robert Hobbs, PhD, DABR, Johns Hopkins University
• QA and QC for Dose Calibrators, SPECT/CT and PET/CT Systems for Radiopharmaceutical Therapy
  • John J. Sunderland, PhD, MBA, The University of Iowa
• Q&A

Radiopharmaceutical Therapy Administration and the Role of the QMP
Moderator: Jacqueline Zoberi, PhD, Washington University School of Medicine

• Panel Session on RPT Administration and the Role of the QMP
  • Jacqueline Zoberi, PhD, Washington University School of Medicine
  • Joseph G. Dise, MMP, AstraZeneca

Access to Therapy and Addressing Unmet Needs
Moderator: Savita V. Dandapani, MD, PhD, City of Hope

• Increasing Access to Radiopharmaceutical Therapy
  • Phillip J. Koo, MD, Prostate Cancer Foundation
• Addressing Unmet Needs in Radiopharmaceutical Therapy
  • Ravi Bhasker Patel, MD, PhD, University of Pittsburgh Medical Center

Plenary Session I
Moderators:
Neil Kanth Taunk, MD, MS, University of Pennsylvania
Jacqueline Zoberi, PhD, Washington University School of Medicine

• Safety and Efficacy of Lu-177 PSMA-617 Versus Established Therapies in mCRPV: Pooled Evidence from Randomized Phase II/III Trials
  • Mohammad Arfat Ganiyani, MBBS, Department of Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami
• Quantitative Ra-223 SPEC/CT for Tumor Dosimetry in Combined SBRT-RPT: Retrospective Analysis from a Phase II Trial
  • David Adam, Phd, MS, Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore
• Phase I Trial Combining Radiopharmaceutical Therapy (RPT) with Total Marrow and Lymphoid Irradiation (TMLI) in Relapsed for Refractory (R/R) AML
  • Savita V. Dandapani, MD, PhD, Department of Radiation Oncology, City of Hope National Medical Center, Duarte, California
• Personalized Multi-Timepoint Voxel-Level Dosimetry in Patients with Metastatic Castration Resistance Prostate Cancer Treated with 177Lu-PSMA-617 Therapy
  • Mustafa Basree, DO, MS, Department of Human Oncology, University of Wisconsin Hospitals and Clinics, Madison, Wisconsin
• Patient-Specific Dosimetry-Based Approaches of I-131 Therapy of Metastatic Cancer
  • Robert Hobbs, PhD, DABR, FAAPM, Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore
• 64Cu-Anti-CEA M5A PET Imaging Pre and Post Neoadjuvant Radiotherapy in Advanced Rectal Cancer
  • Savita V. Dandapani, MD, PhD, Department of Radiation Oncology, City of Hope National Medical Center, Duarte, California
• Factors Influencing Lesion-Level Response After Lu-177 PSMA-Radiogland Therapy on Post-Therapy SPEC/CT with AI-Annotation
  • Gowthan Murugesan, PhD, BAMF Health, Grand Rapids, Michigan
• Hematologic Toxicity Outcomes of Lu-PSMA-617 in Patients Previously Treated with EBRT for Oligometastatic Disease
  • Daniel Rosen, MD, PhD, Department of Radiation Oncology, Brigham and Women's/Dana-Farber Cancer Center, Harvard Medical School, Boston
• Clinical Outcomes among Patients Treated with Lu-PSMA-617 and EBRT for Oligometastatic Prostate Cancer
  • Mai Anh Huynh, MD, PhD, Department of Radiation Oncology, Brigham and Women's/Dana-Farber Cancer Center, Harvard Medical School, Boston

BuildingBeyond Initial Theranostics: Optimizing Operations, Coordination and Outcomes
Moderator: Aprit M. Chhabra, MD, Bridge Oncology, New York Proton Center, Mount Sinai Health System

• Revenue Cycle Management and Prior Authorization Challenges in Theranostic Programs
  • Adam Brown, MBA, NMTCB, Integrated Theranostics Solutions
• Multidisciplinary Care Coordination Across Referring Providers
  • Babak Saboury, MD, PhD, DABR, United Theranostics
• Workflow Optimization: Software Utilization and Tracking Systems
  • Erik Mittra, MD, PhD, Oregon Health and Science University
• Clinical Trials Development in Theranostics Programs: Practical Considerations
  • Adam Brown, MBA, NMTCB, Integrated Theranostics Solutions
• Q&A

Day 2

Experiences in Collaboration: A Tale of 3 Institutions
Moderator: Erin Grady, MD, CCD, Stanford University

• The Penn State Experience
  • Neil Kanth Taunk,MD, MS, University of Pennsylvania
  • Philipose G. Mulugeta, MD, University of Pennsylvania
• The Intermountain Health Experience
  • Dustin L. Boothe, MD, Intermountain Health, Utah Cancer Specialists
  • Eric Hu, MD, MBA, MPH, Intermountain Health, Summit Physician Specialists
• The Stanford Experience
  • Erin Grady, MD, CCD, Stanford University
  • Mallika Marar, MD, MBA, Stanford University
• Q&A

Unique Challenges with Clinical Trials for Radiopharmaceutical Therapy
Moderator: Jeff M. Michalski, MD, MBA, FASTRO, Washington University, St. Louis

• RPT Clinical Trials - An Investigator and Drug Development Perspective
  • Scott T. Tagawa, MD, New York-Presbyterian Hospital/Weill Cornell Medical Center
• RPT Trial Challenges in the National Clinical Trials Network
  • Jonathan E. McConathy, MD, The University of Alabama at Birmingham
• Industry Perspective and Regulatory Challenges for RPT Clinical Trials
  • Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center
• Q&A

Clinical Challenges in Radiopharmaceutical Therapy
Moderator: Ana P. Kiess, MD, PhD, Johns Hopkins University

• Infusion Troubleshooting and Radiation Safety Challenges with RPT
  • Huyn Kim, MD, City of Hope
• Navigating Hematologic and Renal Dysfunction in RPT for Prostate Cancer
  • Russell Z. Szmulewitz, MD, University of Chicago
• Where Should We Stop or Pause Treatment with RPT
  • Ana P. Kiess, MD, PhD, Johns Hopkins University
• Q&A

Looking to the Future: Novel Targets
Moderator: Neil Kanth Taunk,MD, MS, University of Pennsylvania

• Novel Cancer-Specific Targets in Theranostics
  • Freddy E. Escorcia, MD, PhD, RayzeBio
• Pan-cancer Targets in Theranostics
  • Elcin Zan, MD, Cleveland Clinic
• The Potential and Challenges in Alpha Therapy Implementation
  • Suzanne E. Lapi, PhD, The Univeristy of Alabama at Birmingham
• Q&A

Plenary II Session
Moderators:
Robert Hobbs, PhD, DABR, Johns Hopkins University
Terence M. Williams, MD, PhD, City of Hope

• Toward Consensus in Lu-177 RPT Dosimetry: Comparing Multi-Timepoint and Single-Timepoint Imaging in Clinical Implementation
  • Siju George, PhD, Herbert Wertheim College of Medicine, Florida International University, Miami
• Multispecialty Expansion in Radiopharmaceutical Therapy: National Trends from Medicare 2013-2023
  • Sean Maroongroge, MD, MBA, Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA
• Development and Implementation of and Internatl Dosimetry Program to Evaluate Radiotoxicity in Patients Treated with Sequential Lu-177-PSMA and Ac-225-PSMA Radiopharmaceutical Therapy
  • Serguei Castaneda, MD, CB Oncology Partners, Cutler Bay, FL
• A Model of Parallel Radiopharmaceutical Therapy Delivery in Once Large Academic Health System
  • Seema Kacker, MD, PhD, Johns Hopkins University School of Medicine, Baltimore
• A Multidisciplinary Care Process Model for Radiopharmaceutical Therapy Including Both Radiation Oncologists and Nuclear Medicine Physicians as Authorized Users
  • Dustin Boothe, MD, Intermountain Health, Salt Lake City
• Using Virtual Phantoms to Commission the Fitting, Integration, and Dose Calculation for Lu-177 Radiopharmaceutical Therapy Dose Calculations
  • Jose Garcia-Ramirez, MS, WashU Medicine, Department of Radiation Oncology, St. Louis
• From Concept to Clinic: Development and Prototype Inplementation of the Intelligent Radiotherapy Collaboration System for Integrated Radiopharmaceutical Workflows
  • Ranjini Tolakanahalli, PhD, Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami
• Challenges Establishing a Radiopharmaceutical Therapy Clinic within a Radiation Oncology Department in a Community-Based Hospital
  • Danial Sforza, PhD, Department of Radiation Oncology and Molecular Radiation Sciences, School of Medicine, Johns Hopkins University, Baltimore
• Radiopharmaceutical Retreatment
  • Andrew Salner, MD, FASTRO, Hartford HealthCare Cancer Institute, Hartford, CT

Current Status and Challenges of Dosimetry
Moderator: Robert Hobbs, PhD, DABR, Johns Hopkins University

• Status of RPT Dosimtery Methods and Results
  • ​Yuni Derwaraja, MS, PhD, University of Michigan
• QA and Harmonization in RPT
  • ​John J. Sunderland, PhD, MBA, The University of Iowa
• Q&A

Radiobiological and Translational Aspects of RPTs
Moderator: Terence M. Williams, MD, PhD, City of Hope

• The Impact of Dose, Dose Rate, Dose Heterogeneity, and LET on Immuno-Radiobiology and the Translation of RPT
  • Zachary Scott Morris, MD, PhD, University of Wisconsin School of Medicine and Public Health
• Translating Radiolabeled Antibodies from Bench to Bedside
  • ​Anna Wu, PhD, City of Hope
• Q&A